The quality of life of the patient should be a priority in the criteria for funding orphan drugs.

According to the conclusions of the FinMHU-MCDA study which evaluates the factors that determine the funding of treatments for rare diseases, the extent of therapeutic benefit, the severity of the disease or the existence of therapeutic alternatives are also among the most relevant criteria for the multidisciplinary group of experts who have developed the study developed and coordinated by Pharmacoeconomics & Outcomes Research Iberia (PORIB) with the support of AELMHU, the study has made it possible to establish the importance of different criteria for assessing the funding of orphan drugs, considering the preferences of several experts involved in the field of rare diseases. The project was developed in three phases, based on a selection of 13 potentially relevant funding criteria.